The U.S. Food and Drug Administration today approved the blood-thinning drug Brilinta (ticagrelor) to reduce cardiovascular death and heart attack in patients with acute coronary syndromes (ACS). ACS ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved a new administration option for acute coronary syndrome (ACS) ...

AstraZeneca today announced that the US Food and Drug Administration (FDA) has extended the time to complete its review of the New Drug Application (NDA) for ticagrelor (BRILINTA). Accordingly, the ...

(NYSE: AZN) today introduced a creative education program to support patients taking BRILINTA(ticagrelor). Patients who enroll in the program receive support services across multiple channels to help ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) today announced that BRILINTA ® (ticagrelor) tablets received Plan Preferred Tier 2 formulary access on Medco Health Solutions’ National ...

LONDON, Jan 21 (Reuters) - AstraZeneca has replied to U.S. Food and Drug Administration queries about its key new heart drug Brilinta and remains confident about a marketing application for the ...

LONDON (Reuters) - Long-term use of AstraZeneca's drug Brilinta can cut the risk of death, another heart attack or stroke in patients with a history of past attacks by 16 percent, a keenly awaited ...

Bleeding is a risk with all antiplatelet drugs, whose effects pose a problem when patients need surgery or suffer a traumatic injury. A fast-acting reversal agent would make the drug safer to use.

Credit: Getty Images. The FDA has granted Priority Review of the supplemental New Drug Application for Brilinta (ticagrelor; AstraZeneca), for use in combination with aspirin, to reduce the rate of ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Cangrelor infusion in adults with CAD pretreated with ticagrelor was associated with enhanced platelet ...

PhaseBio raised $34 million in its series D round, which will advance its lead assets: a treatment for pulmonary arterial hypertension (PAH) developed in-house and a reversal agent of AstraZeneca’s ...

* Follows failure of heart drug in stroke trial in March * Drugmaker sells rights to Toprol-XL for up to $223 mln (Adds sales forecasts, detail on Toprol-XL deal with Aralez) By Ben Hirschler LONDON, ...